Follow
Christopher B. Ford
Christopher B. Ford
Vice President, Seres Therapeutics
Verified email at serestherapeutics.com
Title
Cited by
Cited by
Year
Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing
PL Lin, CB Ford, MT Coleman, AJ Myers, R Gawande, T Ioerger, ...
Nature medicine 20 (1), 75-79, 2014
5822014
Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis
CB Ford, RR Shah, MK Maeda, S Gagneux, MB Murray, T Cohen, ...
Nature genetics 45 (7), 784-790, 2013
5362013
Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection
CB Ford, PL Lin, MR Chase, RR Shah, O Iartchouk, J Galagan, ...
Nature genetics 43 (5), 482-486, 2011
5342011
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection
P Feuerstadt, TJ Louie, B Lashner, EEL Wang, L Diao, JA Bryant, M Sims, ...
New England Journal of Medicine 386 (3), 220-229, 2022
4002022
The evolution of drug resistance in clinical isolates of Candida albicans
CB Ford, JM Funt, D Abbey, L Issi, C Guiducci, DA Martinez, T Delorey, ...
Elife 4, e00662, 2015
3232015
Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial
EW Yu, L Gao, P Stastka, MC Cheney, J Mahabamunuge, M Torres Soto, ...
PLoS medicine 17 (3), e1003051, 2020
2962020
Magnetic barcode assay for genetic detection of pathogens
M Liong, AN Hoang, J Chung, N Gural, CB Ford, C Min, RR Shah, ...
Nature communications 4 (1), 1752, 2013
2102013
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial
BH McGovern, CB Ford, MR Henn, DS Pardi, S Khanna, EL Hohmann, ...
Clinical infectious diseases 72 (12), 2132-2140, 2021
1482021
Mycobacterium tuberculosis–heterogeneity revealed through whole genome sequencing
C Ford, K Yusim, T Ioerger, S Feng, M Chase, M Greene, B Korber, ...
Tuberculosis 92 (3), 194-201, 2012
1222012
Expression of the Helicobacter pylori adhesin SabA is controlled via phase variation and the ArsRS signal transduction system
AC Goodwin, DM Weinberger, CB Ford, JC Nelson, JD Snider, JD Hall, ...
Microbiology 154 (8), 2231-2240, 2008
1112008
A phase 1b safety study of SER-287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis
MR Henn, EJ O’Brien, L Diao, BG Feagan, WJ Sandborn, C Huttenhower, ...
Gastroenterology 160 (1), 115-127. e30, 2020
872020
DNA replication fidelity in Mycobacterium tuberculosis is mediated by an ancestral prokaryotic proofreader
JM Rock, UF Lang, MR Chase, CB Ford, ER Gerrick, R Gawande, ...
Nature genetics 47 (6), 677-681, 2015
862015
Computational Modeling Predicts IL-10 Control of Lesion Sterilization by Balancing Early Host Immunity–Mediated Antimicrobial Responses with Caseation during Mycobacterium …
NA Cilfone, CB Ford, S Marino, JT Mattila, HP Gideon, JAL Flynn, ...
The Journal of Immunology 194 (2), 664-677, 2015
782015
Coordinated host-pathogen transcriptional dynamics revealed using sorted subpopulations and single macrophages infected with Candida albicans
JF Muñoz, T Delorey, CB Ford, BY Li, DA Thompson, RP Rao, CA Cuomo
Nature communications 10 (1), 1607, 2019
752019
Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection
C Normington, IB Moura, JA Bryant, DJ Ewin, EV Clark, MJ Kettle, ...
NPJ biofilms and microbiomes 7 (1), 16, 2021
662021
Rifampin resistance mutations are associated with broad chemical remodeling of Mycobacterium tuberculosis
N Lahiri, RR Shah, E Layre, D Young, C Ford, MB Murray, SM Fortune, ...
Journal of Biological Chemistry 291 (27), 14248-14256, 2016
662016
Distinct Effects on Diversifying Selection by Two Mechanisms of Immunity against Streptococcus pneumoniae
Y Li, T Gierahn, CM Thompson, K Trzciński, CB Ford, N Croucher, ...
PLoS pathogens 8 (11), e1002989, 2012
542012
SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)
S Khanna, M Sims, TJ Louie, M Fischer, K LaPlante, J Allegretti, ...
Antibiotics 11 (9), 1234, 2022
382022
The mutation rate of mycobacterial repetitive unit loci in strains of M. tuberculosis from cynomolgus macaque infection
MN Ragheb, CB Ford, MR Chase, PL Lin, JAL Flynn, SM Fortune
BMC genomics 14 (1), 145, 2013
312013
Transcriptional heterogeneity of Cryptococcus gattii VGII compared with non-VGII lineages underpins key pathogenicity pathways
RA Farrer, CB Ford, J Rhodes, T Delorey, RC May, MC Fisher, ...
Msphere 3 (5), 2018
162018
The system can't perform the operation now. Try again later.
Articles 1–20